LLY

1,008.05

+0.52%↑

JNJ

229.07

-0.43%↓

ABBV

211.95

-0.25%↓

UNH

396

-0.28%↓

AZN

181.04

-2.08%↓

LLY

1,008.05

+0.52%↑

JNJ

229.07

-0.43%↓

ABBV

211.95

-0.25%↓

UNH

396

-0.28%↓

AZN

181.04

-2.08%↓

LLY

1,008.05

+0.52%↑

JNJ

229.07

-0.43%↓

ABBV

211.95

-0.25%↓

UNH

396

-0.28%↓

AZN

181.04

-2.08%↓

LLY

1,008.05

+0.52%↑

JNJ

229.07

-0.43%↓

ABBV

211.95

-0.25%↓

UNH

396

-0.28%↓

AZN

181.04

-2.08%↓

LLY

1,008.05

+0.52%↑

JNJ

229.07

-0.43%↓

ABBV

211.95

-0.25%↓

UNH

396

-0.28%↓

AZN

181.04

-2.08%↓

Inicio・Lista de Acciones・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Abierto

SectorSanidad

31.13 -0.1

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

31.13

Máximo

31.17

Métricas clave
By Trading Economics
Ingresos	11M 64M
Ventas	-3.2M 149M
P/B Media del Sector	18.542 51.415
BPA	0.68
Margen de beneficios	42.663
Empleados	182
EBITDA	-7.8M 73M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+6.23% upside

Dividendos
By Dow Jones
Próximas Ganancias	5 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	271M 3.8B
Apertura anterior	31.23
Cierre anterior	31.13

Noticias sobre sentimiento de mercado

By Acuity

30%

70%

82 / 346 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

N/A / 24.28 Soporte y Resistencia

Catalyst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 may 2026, 22:44 UTC

Adquisiciones, fusiones, absorciones

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 may 2026, 22:27 UTC

Adquisiciones, fusiones, absorciones

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 may 2026, 22:12 UTC

Ganancias

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 may 2026, 21:52 UTC

Adquisiciones, fusiones, absorciones

LVMH to Sell Marc Jacobs

15 may 2026, 00:00 UTC

Ganancias

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 may 2026, 23:57 UTC

Adquisiciones, fusiones, absorciones

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 may 2026, 23:56 UTC

Adquisiciones, fusiones, absorciones

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 may 2026, 23:56 UTC

Adquisiciones, fusiones, absorciones

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 may 2026, 23:56 UTC

Charlas de Mercado

Gold Prices Rise on Strong Demand -- Market Talk

14 may 2026, 23:56 UTC

Adquisiciones, fusiones, absorciones

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 may 2026, 23:50 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 may 2026, 23:50 UTC

Charlas de Mercado

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 may 2026, 23:47 UTC

Ganancias

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 may 2026, 23:47 UTC

Ganancias

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 may 2026, 23:46 UTC

Ganancias

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 may 2026, 23:46 UTC

Ganancias

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 may 2026, 23:28 UTC

Charlas de Mercado

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 may 2026, 23:00 UTC

Charlas de Mercado

Australia's One Nation Party Leads In The Polls -- Market Talk

14 may 2026, 22:46 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 may 2026, 22:46 UTC

Charlas de Mercado

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 may 2026, 22:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

14 may 2026, 22:35 UTC

Charlas de Mercado

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 may 2026, 22:11 UTC

Adquisiciones, fusiones, absorciones

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 may 2026, 22:06 UTC

Charlas de Mercado

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 may 2026, 22:04 UTC

Ganancias

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 may 2026, 22:04 UTC

Ganancias

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 may 2026, 22:04 UTC

Ganancias

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 may 2026, 22:00 UTC

Ganancias

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 may 2026, 21:55 UTC

Ganancias

Nu Holdings 1Q EPS 18c >NU

14 may 2026, 21:55 UTC

Ganancias

Nu Holdings 1Q Rev $4.97B >NU

Comparación entre iguales

Cambio de precio

Catalyst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

6.23% repunte

Estimación a 12 Meses

Media 33.1 USD 6.23%

Máximo 35 USD

Mínimo 31.5 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

N/A / 24.28Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentimiento

By Acuity

82 / 346 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.